ClinicalTrials.gg
CompletedNCT00303108Updated Nov 3, 2016Results posted

Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer

A Phase 2 interventional study of Pegylated liposomal doxorubicin and Carboplatin in Metastatic Breast Cancer, sponsored by US Oncology Research. Completed at 57 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-03.

Sponsored by US Oncology Research (part of Sarah Cannon Research Institute) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
136
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies testing liposomal doxorubicin in Breast Neoplasms — 5 open to participants now, 9 under way, 2 of them phase 3. liposomal doxorubicin · Breast Neoplasms.

Enrollment
17th of 66
136 · median 57
Started
2005
with 4 others
Phase 2
37 of 67
2 open now
Registered
14th of 67
by date

Among the 67 studies testing liposomal doxorubicin in Breast Neoplasms, this one is the 17th largest by enrollment of the 66 interventional ones that give a count, is one of 5 that started in 2005, is one of 37 in phase 2, and was the 14th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

5 of the 67 studies testing liposomal doxorubicin in Breast Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About liposomal doxorubicin

liposomal doxorubicin: first FDA approval 1995 (DOXIL (LIPOSOMAL)), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing liposomal doxorubicin in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine the ORR associated with Doxil in combination with carboplatin in HER2- (negative) MBC (and with Herceptin in HER2+ MBC).

03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has breast cancer with documented - or HER2+ (IHC3+ or FISH+) disease
  • Has measurable MBC, with at least 1 per criteria (see Section 10). Irradiated lesions cannot be used to assess response but can be used to assess progression.
  • Has had no prior treatment with Doxil or carboplatin; may have had Herceptin if treatment was completed more than 1 year prior to study
  • Has had no adjuvant chemotherapy within 1 year prior to study, but may have received prior anthracyclines as adjuvant chemotherapy
  • For taxane-pretreated patients (adjuvant or metastatic), has had no more than 1 prior chemotherapy regimen for MBC
  • For taxane-naïve patients, has had no prior chemotherapy for MBC
  • Has had cumulative doses of \< 300 mg/m2 prior doxorubicin or \< 450 mg/m2 prior epirubicin
  • Has normal cardiac function as evidenced by a within institutional normal limits by multiple gated acquisition (MUGA) scan. An echocardiogram (ECHO) may be used if MUGA is not available, but the same test must be used throughout the study to evaluate LVEF.
  • Has an Performance Status (PS) 0-2 (see Appendix I)
  • Is a male or female greater than or equal to 18 years of age
  • Laboratory Values - Please refer to protocol section 4.2 for specific laboratory values.
  • Has a negative serum pregnancy test within 7 days prior to registration (woman of [WOCBP; not surgically sterilized and between menarche and 1 year ])
  • If fertile, patient (male or female) has agreed to use an acceptable method of (eg, abstinence, intrauterine device, oral contraceptives, barrier device with spermicide or surgical sterilization) to avoid pregnancy for the duration of the study and for a period of 3 months thereafter.
  • Has signed a Patient Form
  • Has signed a Patient Authorization Form (HIPAA Form)
  • Has a of > 3 months

Exclusion criteria

Exclusion Criteria:

  • Has had a myocardial infarction (MI) within 6 months of trial enrollment, or has (NYHA; see Appendix IV) Class II or greater heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, pericardial disease, or electrocardiographic evidence of acute ischemic or active conduction system abnormalities
  • Has a history of reactions attributed to a conventional formulation of doxorubicin HCL or the components of Doxil
  • Has evaluable only disease; eg, bone only, pleural, peritoneal only disease
  • Is receiving concurrent immunotherapy, hormonal therapy, or radiation therapy. Patients receiving therapy for disease may enroll on the trial after a drug of 2 weeks.
  • Is receiving concurrent therapy or has received such therapy within 30 days
  • Has evidence of requiring and/or radiation or any documented
  • Has a serious uncontrolled intercurrent medical or psychiatric illness, including serious infection or history of uncontrolled seizures, CNS disorders deemed by the Treating Physician to be clinically significant, precluding
  • Has a history of other within the last 5 years (except cured basal cell carcinoma of skin and carcinoma in situ of uterine cervix), which could affect the diagnosis or assessment of any of the study drugs
  • Is a pregnant or lactating woman
  • Is unable to comply with requirements of study
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    Arm 1

    Patients will receive IV Doxil 30 mg/m2 and carboplatin AUC=5 on Day 1 of each cycle. A cycle consists of 28 days. In addition, HER2+ (IHC3+ and FISH+) patients only will receive a one-time loading dose of Herceptin 8 mg/kg IV on Day 1 of Cycle 1 and 4 mg/kg on Day 1 and Day 15 of every cycle thereafter.

    Drug: Pegylated liposomal doxorubicin · Drug: Carboplatin · Drug: trastuzumab

Interventions

  • 30 mg/m2 IV on Day 1 of each 28 day cycle

    Also known as: Doxil

  • AUC=5 on Day 1 of each 28 day cycle

  • 4 mg/kg on Days 1 and 15 of each cycle(loading dose of 8 mg/kg on Day 1 of Cycle 1 only)

    Also known as: Herceptin

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Objective response (OR) = CR + PR.

    Time frame: From date of randomization until the date of first documented progression or date of intolerable toxicity, whichever came first, assessed up to 54 months.

Secondary outcomes

  1. Duration of Response

    Duration from date of stating treatment to the date of first CR or PR.

    Time frame: From date of randomization until the date of first documented progression or date of intolerable toxicity, whichever came first, assessed up to 54 months.

  2. Progression-free Survival (PFS)

    PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date. Progression is defined as appearance of one or more new lesions. Unequivocal progression of existing non-target lesions. Although a clear progression of "non-target" lesions only is exceptional, in such circumstances, the opinion of the Treating Physician should prevail, and the progression status should be confirmed at a later time by the review panel.

    Time frame: 30 months

  3. 1-year Overall Survival

    OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.

    Time frame: 1 year

07

Results

Posted Nov 3, 2016

Participant flow

Participant flow — Overall Study
MilestoneD+C and Taxane NaiveD+C and Taxane PretreatedD+C+H
Started434647
Completed313731
Not completed12916
Withdrew: Adverse event567
Withdrew: Patient request428
Withdrew: Failed entry101
Withdrew: Ineligible210

Outcome measures

PrimaryObjective Response Rate (ORR)

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Objective response (OR) = CR + PR.

Time frame:
From date of randomization until the date of first documented progression or date of intolerable toxicity, whichever came first, assessed up to 54 months.
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsD+C and Taxane NaiveD+C and Taxane PretreatedD+C+H
Objective Response Rate (ORR)30.8 (17.0 to 47.6)31.0 (17.6 to 47.1)55.6 (40.0 to 70.4)
SecondaryDuration of Response

Duration from date of stating treatment to the date of first CR or PR.

Time frame:
From date of randomization until the date of first documented progression or date of intolerable toxicity, whichever came first, assessed up to 54 months.
Reported as:
Median · months
Duration of Response
monthsD+C and Taxane NaiveD+C and Taxane PretreatedD+C+H
Duration of Response11.1 (0.9 to 15.2)7.0 (2.8 to 13.2)11.8 (2.3 to 16.8)
SecondaryProgression-free Survival (PFS)

PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date. Progression is defined as appearance of one or more new lesions. Unequivocal progression of existing non-target lesions. Although a clear progression of "non-target" lesions only is exceptional, in such circumstances, the opinion of the Treating Physician should prevail, and the progression status should be confirmed at a later time by the review panel.

Time frame:
30 months
Reported as:
Median · months
Progression-free Survival (PFS)
monthsD+C and Taxane NaiveD+C and Taxane PretreatedD+C+H
Progression-free Survival (PFS)8.1 (0.3 to 28.5)5.4 (0.1 to 21.0)10.1 (0.2 to 18.5)
Secondary1-year Overall Survival

OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.

Time frame:
1 year
Reported as:
Number · probability of overall survival
1-year Overall Survival
probability of overall survivalD+C and Taxane NaiveD+C and Taxane PretreatedD+C+H
1-year Overall Survival0.83 (0.67 to 0.915)0.56 (0.40 to 0.69)0.90 (0.76 to 0.96)

Adverse events

Collected over During the whole treatment period, up to 30 days following last dose.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
D+C and Taxane Naive or Pretreated—8/83 (9.6%)80/83 (96.4%)
D+C+H—3/46 (6.5%)44/46 (95.7%)
Most frequent serious events
Most frequent serious events
EventD+C and Taxane Naive or PretreatedD+C+H
NAUSEA AND VOMITINGGastrointestinal disorders0/832/46
DEHYDRATIONGastrointestinal disorders2/830/46
THROMBOCYTOPENIABlood and lymphatic system disorders2/830/46
PNEUMONIARespiratory, thoracic and mediastinal disorders0/831/46
VOMITINGGastrointestinal disorders1/831/46
ANEMIABlood and lymphatic system disorders1/830/46
ANOREXIAGastrointestinal disorders1/830/46
PANCYTOPENIABlood and lymphatic system disorders1/830/46
RENAL FAILURE ACUTERenal and urinary disorders1/830/46
URINARY TRACT INFECTIONRenal and urinary disorders1/830/46
Most frequent other events
Showing 10 of 32
Most frequent other events
EventD+C and Taxane Naive or PretreatedD+C+H
ANEMIABlood and lymphatic system disorders48/8330/46
NAUSEAGastrointestinal disorders43/8329/46
NEUTROPENIABlood and lymphatic system disorders40/8326/46
WEAKNESSGeneral disorders40/8323/46
THROMBOCYTOPENIABlood and lymphatic system disorders35/8314/46
LEUCOPENIABlood and lymphatic system disorders21/8318/46
ALOPECIASkin and subcutaneous tissue disorders11/8315/46
VOMITINGGastrointestinal disorders16/8312/46
CONSTIPATIONGastrointestinal disorders20/838/46
ANOREXIAGastrointestinal disorders12/8311/46

Baseline characteristics

ITT population

Age, Continuous
Age, Continuous(years)D+C and Taxane NaiveD+C and Taxane PretreatedD+C+HTotal
Median61.0 (28.0 to 84.9)51.7 (29.8 to 72.3)54.1 (29.0 to 77.6)56.4 (28.0 to 84.9)
Sex: Female, Male
Sex: Female, Male(Participants)D+C and Taxane NaiveD+C and Taxane PretreatedD+C+HTotal
Female424647135
Male1001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)D+C and Taxane NaiveD+C and Taxane PretreatedD+C+HTotal
Caucasian303437101
Black108725
Hispanic3429
Hawaiian0011
Region of Enrollment
Region of Enrollment(participants)D+C and Taxane NaiveD+C and Taxane PretreatedD+C+HTotal
United States434647136
08

Study locations

57 sites
  • Birmingham Hematology and Oncology
    Birmingham, Alabama 35205, United States
  • Hematology Oncology Associates
    Phoenix, Arizona 85012, United States
  • Northern AZ Hematology & Oncology Associates-Sedona
    Sedona, Arizona 86336, United States
  • Rocky Mountain Cancer Center-Rose
    Denver, Colorado 80220, United States
  • Florida Cancer Institute
    New Port Richey, Florida 34655, United States
  • Ocala Oncology Center
    Ocala, Florida 34474, United States
  • Hematology Oncology Associates of IL
    Chicago, Illinois 60611, United States
  • Cancer Care & Hematology Specialists of Chicagoland, PC
    Niles, Illinois 60714, United States
  • Central Indiana Cancer Centers
    Indianapolis, Indiana 46227, United States
  • Kansas City Cancer Centers-Southwest
    Overland Park, Kansas 66210, United States
  • Maryland Oncology Hematology, PA
    Columbia, Maryland 21044, United States
  • Flavio Kruter, MD, PA
    Westminster, Maryland 21157, United States
  • Minnesota Oncology Hematology, PA
    Minneapolis, Minnesota 55404, United States
  • Missouri Cancer Associates
    Columbia, Missouri 65201, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89109, United States
  • New Mexico Cancer Care Associates
    Santa Fe, New Mexico 87505, United States
  • New York Oncology Hematology, PC
    Albany, New York 12208, United States
  • Ruth Oratz MD
    New York, New York 10016, United States
  • Raleigh Hematology Oncology Associates
    Cary, North Carolina 27511, United States
  • Greater Dayton Cancer Center
    Kettering, Ohio 45409, United States
  • Willamette Vallejy Cancer Center
    Eugene, Oregon 97401, United States
  • Medical Oncology Associates
    Kingston, Pennsylvania 18704, United States
  • Texas Cancer Center - Abilene (South)
    Abilene, Texas 79606, United States
  • Texas Oncology, P.A.-Amarillo
    Amarillo, Texas 79106, United States
  • Texas Cancer Center
    Arlington, Texas 76014, United States
  • Mamie McFaddin Ward Cancer Center
    Beaumont, Texas 77702, United States
  • Texas Oncology, PA-Bedford
    Bedford, Texas 76022, United States
  • Texas Cancer Center at Medical City
    Dallas, Texas 75230, United States
  • Texas Oncology, PA
    Dallas, Texas 75231, United States
  • The TexasCancer Center
    Dallas, Texas 75237, United States
  • Texas Oncology, PA
    Dallas, Texas 75246, United States
  • Texas Cancer Center-Denton
    Denton, Texas 76210, United States
  • El Paso Cancer Treatment Ctr
    El Paso, Texas 79915, United States
  • Texas Oncology, PA
    Fort Worth, Texas 76104, United States
  • Texas Oncology, PA
    Garland, Texas 75042, United States
  • Texas Oncology, PA
    Houston, Texas 77024, United States
  • Lake Vista Cancer Center
    Lewisville, Texas 75067, United States
  • Longview Cancer Center
    Longview, Texas 75601, United States
  • South Texas Cancer Center-McAllen
    McAllen, Texas 78503, United States
  • Texas Cancer Center of Mesquite
    Mesquite, Texas 75150, United States
  • Alison Cancer Center
    Midland, Texas 79701, United States
  • West Texas Cancer Center
    Odessa, Texas 79761, United States
  • Paris Regional Cancer Center
    Paris, Texas 75460, United States
  • HOAST-Medical Dr.
    San Antonio, Texas 78229, United States
  • Texas Cancer Center-Sherman
    Sherman, Texas 75090, United States
  • Texas Oncology Cancer Center-Sugar Land
    Sugar Land, Texas 77479, United States
  • Tyler Cancer Center
    Tyler, Texas 75702, United States
  • Texas Oncology Cancer Care and Research Center-Waco
    Waco, Texas 76712, United States
  • Texas Oncology, P.A.
    Webster, Texas 77598, United States
  • Fairfax Northern VA Hem-Onc PC
    Fairfax, Virginia 22031, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
  • Onc and Hem Associates of SW VA, Inc
    Salem, Virginia 24153, United States
  • Puget Sound Cancer Center-Edmonds
    Edmonds, Washington 98026, United States
  • Puget Sound Cancer Center-Seattle
    Seattle, Washington 98133, United States
  • Cancer Care Northwest-North
    Spokane, Washington 99218, United States
  • Northwest Cancer Specialists-Vancouver
    Vancouver, Washington 98684, United States
  • Yakima Valley Mem Hosp/North Star Lodge
    Yakima, Washington 98902, United States
09

References and documents

Publications

  • Collea RP, Kruter FW, Cantrell JE, George TK, Kruger S, Favret AM, Lindquist DL, Melnyk AM, Pluenneke RE, Shao SH, Crockett MW, Asmar L, O'Shaughnessy J. Pegylated liposomal doxorubicin plus carboplatin in patients with metastatic breast cancer: a phase II study. Ann Oncol. 2012 Oct;23(10):2599-2605. doi: 10.1093/annonc/mds052. Epub 2012 Mar 19. PubMed 22431702 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005, a primary completion of Mar 2010 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 6 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2006
First posted
Mar 15, 2006
Start
Dec 2005
Primary completionActual
Mar 2010
CompletionActual
Jun 2011
Results first posted
Nov 3, 2016
Last update
Nov 3, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00303108
Collaborators
Ortho Biotech, Inc., Tibotec Pharmaceutical Limited
Responsible party
Sponsor
First posted
Mar 15, 2006
Start date
Dec 2005
Primary completion
Mar 2010
Completion
Jun 2011
Results posted
Nov 3, 2016
Last update
Nov 3, 2016

Study contacts

Rufus P Collea, MD
principal investigator · US Oncology Research
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Liposomal doxorubicin · Carboplatin

Start the discussion